BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Sabre//Sabre VObject 3.5.3//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:gwbase-vobject-54f221e9-dfab-4942-baf2-54207fdcbd9a
SUMMARY:14th European Congress on Epileptology
DTSTAMP:20260515T135134Z
DTSTART:20200705T060000Z
ORGANIZER;CN=epilepsiselskapet:mailto:noreply@epilepsiselskapet.no
DESCRIPTION: \n5-9 July 2020 | Geneva\, Switzerland\n\nhttps://ww
w.epilepsycongress.org/ece/award-nominations/\n[https://www.epilepsycongre
ss.org/ece/award-nominations/]\n\n \n\nMAIN SESSIONS\n[https://www.ep
ilepsycongress.org/ece/programme/#main-sessions]\n\nCHAIRS’ SYMPOSIUM: P
RECISION MEDICINE FOR PATIENTS WITH EPILEPSY –\nARE WE THERE YET?\n\n_Co
-chairs: Eugen Trinka (Austria) & Margitta Seeck (Switzerland)_\n\n * How
genetic findings impact patients’ treatment and prognosis\n– _Sarah
Weckhuysen (Belgium)_\n * New imaging tools will advance patients’ diag
nosis and treatment\nto the next level – _Serge Vulliemoz (Switzerland)
_\n * New avenues in drug development will have an impact on patients’\
nlife – _Wolfgang Löscher (Germany)_\n * What is needed to bring adva
nces in diagnosis and treatment to the\npopulation? – The global impleme
ntation gap – _Samuel Wiebe\n(Canada)_\n\n \n\nNEURODEGENERATION AND E
PILEPSY \n\n_Co-chairs: Eleonora Aronica (Netherlands) & Stephan Rüegg\n
(Switzerland)_\n\n * Neurodegenerative disorders and seizures – the epi
demiological\nview – _Ettore Beghi (Italy) _\n * The ABT of neurodege
neration: alpha synuclein\, beta amyloid\, and\ntau protein and their role
in epileptogenesis – _Katja Kobow\n(Germany)_\n * Diagnosis – neuro
imaging\, CSF\, EEG – _Giovani Frisoni\n(Italy) _\n * Therapeutic cha
llenges of treating patients with epilepsy and\nneurodegenerative disorder
s – _Stephan Rüegg (Switzerland)_\n * The birth of hyperexcitability
in Alzheimer’s Disease\n– _Jeffrey Noebels (USA)_\n\n \n\nNOVEL APPR
OACHES TO DRUG DISCOVERY\n\n_Co-chairs: Matthew Walker (United Kingdom) &
Meir Bialer (Israel)_\n\n * Why we need novel approaches – _Heidrun Po
tschka (Germany)_\n * Novel models of paediatric epilepsies – _Stépha
ne Auvin\n(France)_\n * Zebra fish as tools for personalised medicine –
_Peter de Witte\n(Belgium)_\n * Use of gene networks and induced plurip
otent stem cells in drug\ndiscovery – _Michael Johnson (United Kingdom)
_\n\n \n\nIS IT POSSIBLE TO PREDICT OUTCOME IN CHILDHOOD EPILEPSIES?\n\n_
Co-chairs: Nicola Specchio (Italy) & Georgia Ramantani (Switzerland)_\n\n
* The role of genetics: where to start for understanding outcome\n– _I
ngrid Scheffer (Australia)_\n * Disease modifying treatments: is there an
option? – _Nicola\nSpecchio (Italy)_\n * Prediction of outcome after
epilepsy surgery: what can we learn\nfrom the virtual brain? – _Fabrice
Bartolomei (France)_\n * How EEG\, MRI and neuroimaging of brain network
s can help?\n– _Torsten Baldeweg (United Kingdom)_\n * The sooner\, th
e better – _Georgia Ramantani (Switzerland)_\n\n \n\nFUTURE THERAPIES
FOR EPILEPSY\n\n_Co-chairs: Reetta Kälviäinen (Finland) & Meir Bialer (I
srael)_\n\n * Update on new antiepileptic drugs in the pipeline – _Mei
r\nBialer (Israel)_\n * Can we develop new therapies for therapy-resistan
t patients?\n– _Matthew Walker (United Kingdom)_\n * Impact of new reg
ulatory guidelines on drug development approaches\n– _Emilio Perucca (I
taly)_\n * Innovative treatments for orphan epilepsies\, one at a time?\n
– _J Helen Cross (United Kingdom)_\n * Update on new antiepileptic dev
ices in the pipeline – _Kristl\nVonck (Belgium)_\n\n
X-ALT-DESC;FMTTYPE=text/html:\n\n\n14th European Congress on Epileptology
\n\n5-9 July 2020 \; \;| \; \;Geneva\,
Switzerland
https://www.epilepsycongress.org/ece/award-nomin
ations/
\; \; \;
\n
Chairs’ Symposium:
Precision medicine for patients with epilepsy – are we there yet?
Co-chairs: Eugen Trinka (Austria) &\; Margitta Seeck (Switzerlan
d)
\n\n\n- How genetic findings impact patients’ treatment
and prognosis – \;Sarah Weckhuysen (Belgium)
\n\n- New
imaging tools will advance patients’ diagnosis and treatment to the next
level – \;Serge Vulliemoz (Switzerland)
\n\n- New aven
ues in drug development will have an impact on patients’ life – \;
Wolfgang Löscher (Germany)
\n\n- What is needed to bring adv
ances in diagnosis and treatment to the population? – The global impleme
ntation gap – \;Samuel Wiebe (Canada)
\n\n
\n
\;
Neurodegeneration and epilepsy \;
Co-chairs:
Eleonora Aronica (Netherlands) &\; Stephan Rüegg (Switzerland)
\n\n\n- Neurodegenerative disorders and seizures – the epidemiolog
ical view – \;Ettore Beghi (Italy) \;
\n\n- The ABT
of neurodegeneration: alpha synuclein\, beta amyloid\, and tau protein an
d their role in epileptogenesis – \;Katja Kobow (Germany)
\n\n- Diagnosis – neuroimaging\, CSF\, EEG – \;Giovani Friso
ni (Italy) \;
\n\n- Therapeutic challenges of treating patie
nts with epilepsy and neurodegenerative disorders – \;Stephan Rü
egg (Switzerland)
\n\n- The birth of hyperexcitability in Alzhei
mer’s Disease – \;Jeffrey Noebels (USA)
\n\n
\n&
nbsp\;
Novel approaches to drug discovery
Co-chairs:
Matthew Walker (United Kingdom) &\; Meir Bialer (Israel)
\n
\n\n- Why we need novel approaches – \;Heidrun Potschka (German
y)
\n\n- Novel models of paediatric epilepsies – \;Sté
phane Auvin (France)
\n\n- Zebra fish as tools for personalised
medicine – \;Peter de Witte (Belgium)
\n\n- Use of gene
networks and induced pluripotent stem cells in drug discovery – \;<
i>Michael Johnson (United Kingdom)
\n\n
\n \;
Is it possible to predict outcome in childhood epilepsies?
Co
-chairs: Nicola Specchio (Italy) &\; Georgia Ramantani (Switzerland)
\n\n\n- The role of genetics: where to start for understanding
outcome – \;Ingrid Scheffer (Australia)
\n\n- Disease m
odifying treatments: is there an option? – \;Nicola Specchio (Ita
ly)
\n\n- Prediction of outcome after epilepsy surgery: what can
we learn from the virtual brain? – \;Fabrice Bartolomei (France)
\n\n- How EEG\, MRI and neuroimaging of brain networks can help
? – \;Torsten Baldeweg (United Kingdom)
\n\n- The soone
r\, the better – \;Georgia Ramantani (Switzerland)
\n\n\n \;
Future therapies for epilepsy
Co-cha
irs: Reetta Kälviäinen (Finland) &\; Meir Bialer (Israel)
\n\n\n- Update on new antiepileptic drugs in the pipeline – \;M
eir Bialer (Israel)
\n\n- Can we develop new therapies for thera
py-resistant patients? – \;Matthew Walker (United Kingdom)\n\n
- Impact of new regulatory guidelines on drug development approach
es – \;Emilio Perucca (Italy)
\n\n- Innovative treatmen
ts for orphan epilepsies\, one at a time? – \;J Helen Cross (Unit
ed Kingdom)
\n\n- Update on new antiepileptic devices in the pip
eline – \;Kristl Vonck (Belgium)
\n\n
\n
END:VEVENT
END:VCALENDAR